Diferencia entre revisiones de «Ipratropium»
(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: Atrovent ==Adult Dosing== ===Asthma=== *0.5mg q20min x3 ==Pediatric Dosing== ==Special Populations== *Drug Rat...") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestran 19 ediciones intermedias de 6 usuarios) | |||
| Línea 1: | Línea 1: | ||
==General== | ==General== | ||
*Type: | *Type: Anticholinergic Agent | ||
*Dosage Forms: | *Dosage Forms: Oral inhalation | ||
*Common Trade Names: Atrovent | *Common Trade Names: Atrovent | ||
==Adult Dosing== | ==Adult Dosing== | ||
[[Asthma]]: 0.5mg Nebulized q20min, up to 3 doses<br /> | |||
[[COPD]]: 0.5mg Nebulized q20mins, up to 3 doses | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
[[Asthma]] | |||
*Children ≤5 years: 0.25mg Neb q20mins, up to 3 doses | |||
*Children ≤12 years: 0.25-0.5mg Neb q20mins, up to 3 doses | |||
*Children >12 years: Refer to adult dosing | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *[[Lactation risk categories]]: L3 | ||
*Renal Dosing | *Renal Dosing - none | ||
*Hepatic Dosing - none | |||
*Hepatic Dosing | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to | *Allergy to anticholenergics (Atropine, Ipatropium) | ||
*Not to be used as sole rescue agent in acute exacerbation | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Death | |||
===Common=== | ===Common=== | ||
*Urinary retention | |||
*Increased intraocular pressure | |||
*Bitter taste in mouth | |||
*Dry throat/Cough | |||
*Nasal dryness | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2-5hrs | ||
*Metabolism: | *Metabolism: Possible ester hydrolysis | ||
*Excretion: | *Excretion: Fecal and Renal | ||
*Mechanism of Action: | *Mechanism of Action: Cholinergic antagonist of acetylcholine at the cholinergic receptors, causing dilatation of bronchial smooth muscle and decreased serous and seromucous glands secretion. | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ipratropium]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] | |||
[[Category:Pulmonology]] | |||
Revisión actual - 21:55 20 mar 2026
General
- Type: Anticholinergic Agent
- Dosage Forms: Oral inhalation
- Common Trade Names: Atrovent
Adult Dosing
Asthma: 0.5mg Nebulized q20min, up to 3 doses
COPD: 0.5mg Nebulized q20mins, up to 3 doses
Pediatric Dosing
- Children ≤5 years: 0.25mg Neb q20mins, up to 3 doses
- Children ≤12 years: 0.25-0.5mg Neb q20mins, up to 3 doses
- Children >12 years: Refer to adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation risk categories: L3
- Renal Dosing - none
- Hepatic Dosing - none
Contraindications
- Allergy to anticholenergics (Atropine, Ipatropium)
- Not to be used as sole rescue agent in acute exacerbation
Adverse Reactions
Serious
- Death
Common
- Urinary retention
- Increased intraocular pressure
- Bitter taste in mouth
- Dry throat/Cough
- Nasal dryness
Pharmacology
- Half-life: 2-5hrs
- Metabolism: Possible ester hydrolysis
- Excretion: Fecal and Renal
- Mechanism of Action: Cholinergic antagonist of acetylcholine at the cholinergic receptors, causing dilatation of bronchial smooth muscle and decreased serous and seromucous glands secretion.
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute asthma exacerbation | 0.25-0.5 mg nebulized q20min x2-3 doses | Anticholinergic adjunct (acute setting only) | Nebulized | Adult |
| Acute asthma exacerbation (peds) | 0.25-0.5mg q20min x3 (with first 3 albuterol doses) | Adjunctive anticholinergic; reduces admissions | Nebulized | Pediatric |